Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer’s DiseaseA Markov Model in Finland

被引：0
|
作者：
Clément François
Harri Sintonen
Raimo Sulkava
Benoît Rive
机构：
[1] Lundbeck SA,
[2] University of Helsinki,undefined
[3] University of Kuopio,undefined
[4] Altipharm SA,undefined
来源：
Clinical Drug Investigation | 2004年 / 24卷
关键词：
Memantine; Memantine Treatment; Mini Mental State Evaluation; Constant Annualise Rate; Memantine Therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：373 / 384
页数：11
相关论文
共 50 条
  • [1] Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease -: A Markov model in Finland
    François, C
    Sintonen, H
    Sulkava, R
    Rive, B
    [J]. CLINICAL DRUG INVESTIGATION, 2004, 24 (07) : 373 - 384
  • [2] Memantine in Moderately-Severe-to-Severe Alzheimer’s DiseaseA Postmarketing Surveillance Study
    Francesca Clerici
    Nicola Vanacore
    Antonietta Elia
    Stefania Spila-Alegiani
    Simone Pomati
    Roberto Da Cas
    Roberto Raschetti
    Claudio Mariani
    [J]. Drugs & Aging, 2009, 26 : 321 - 332
  • [3] Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer's disease in Spain
    Antonanzas, F
    Badenas, J
    François, C
    Guilhaume, C
    [J]. VALUE IN HEALTH, 2003, 6 (06) : 765 - 765
  • [4] A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease
    Kirby, Joanna
    Green, Colin
    Loveman, Ennna
    Clegg, Andrew
    Picot, Joanna
    Takeda, Andrea
    Payne, Elizabeth
    [J]. DRUGS & AGING, 2006, 23 (03) : 227 - 240
  • [5] A Systematic Review of the Clinical and Cost-Effectiveness of Memantine in Patients with Moderately Severe to Severe Alzheimer’s Disease
    Joanna Kirby
    Colin Green
    Emma Loveman
    Andrew Clegg
    Joanna Picot
    Andrea Takeda
    Elizabeth Payne
    [J]. Drugs & Aging, 2006, 23 : 227 - 240
  • [6] Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway
    Rive, B.
    Aarsland, D.
    Grishchenko, M.
    Cochran, J.
    Lamure, M.
    Toumi, M.
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2012, 27 (06) : 573 - 582
  • [7] Memantine in Moderately-Severe-to-Severe Alzheimer's Disease A Postmarketing Surveillance Study
    Clerici, Francesca
    Vanacore, Nicola
    Elia, Antonietta
    Spila-Alegiani, Stefania
    Pomati, Simone
    Da Cas, Roberto
    Raschetti, Roberto
    Mariani, Claudio
    [J]. DRUGS & AGING, 2009, 26 (04) : 321 - 332
  • [8] Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)
    Agueera-Ortiz, Luis F.
    [J]. REVISTA DE NEUROLOGIA, 2010, 51 (09) : 525 - 534
  • [9] COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DISEASE IN NORWAY
    Toumi, M.
    Lamure, M.
    Grishchenko, M.
    Cochran, J.
    Rive, B.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A370 - A370
  • [10] Treatment benefits of memantine in moderately severe to severe Alzheimer's disease patients with behavioural symptoms
    Wilcock, G.
    Ballard, C.
    Cooper, J.
    Loft, H.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 72 - 72
12345